论文部分内容阅读
目的探讨神经节苷脂联合依达拉奉治疗大面积脑梗死的临床疗效。方法将发病48h内的大面积脑梗死的病人74例,随机分入治疗组和对照组。对照组应用神经节苷脂注射液60mg静脉滴注,1次/d,共21d,同时给予阿司匹林、低分子肝素作为基础治疗;治疗组应用神经节苷脂注射液60mg,1次/d,同时给予依达拉奉注射液30mg静脉滴注,2次/d,共21d。发病72h和治疗后定期对患者行欧洲卒中评分(ESS)、日常生活活动能力(ADL)评分,以治疗21dESS的评分和第90d的ADL评分作为主要疗效判断标准。结果21d后联合治疗组和对照组的ESS评分分别为(67.32±15.36)、(50.21±13.04),两组相比差异有显著性(p<0.01);90d后治疗组、对照组ADL(改良Barthel指数)评分分别为(75.38±20.56)、(54.63±28.59),两组相比有差异有显著性(p<0.01)。结论神经节苷脂联合依达拉奉治疗大面积脑梗死疗效明显。
Objective To investigate the clinical effect of ganglioside and edaravone in treating large area cerebral infarction. Methods 74 cases of large-area cerebral infarction within 48 hours after onset were randomly divided into treatment group and control group. In the control group, 60 mg of ganglioside injection 60 mg once daily for 16 days was administered intravenously once a day for as long as 21 days. Aspirin and low molecular weight heparin were given as the basic treatment. Given edaravone 30mg intravenous infusion, 2 times / d, a total of 21d. The incidence of European stroke (ESS), daily living activity (ADL) scores were assessed 72h after onset and after treatment. The scores of 21dESS and 90th ADL were taken as the main criteria of efficacy. Results After 21 days, the ESS scores of the combination therapy group and the control group were (67.32 ± 15.36) and (50.21 ± 13.04) respectively, there was significant difference between the two groups (p <0.01) Barthel index scores were (75.38 ± 20.56) and (54.63 ± 28.59) respectively, there was significant difference between the two groups (p <0.01). Conclusion Ganglioside combined with edaravone treatment of large area cerebral infarction obvious effect.